Featured Research

from universities, journals, and other organizations

Chemists' Study Of Protein May Provide Insights Into Heart Disease And Cancer

Date:
August 11, 2006
Source:
University of California - Los Angeles
Summary:
UCLA chemists studying a protein associated with a rare genetic disease may also be gaining insights into cancer and heart disease.

UCLA chemists Carla Koehler and Steven Claypool are the first scientists to show the location of the tafazzin protein in the cell's mitochondria.
Credit: Carla Koehler/UCLA Chemistry and Biochemistry

UCLA chemists studying a protein associated with a rare genetic disease may also be gaining insights into cancer and heart disease.

Related Articles


Carla Koehler, a UCLA associate professor of chemistry and biochemistry, and Steven Claypool, a UCLA postdoctoral scholar in chemistry and biochemistry, report in the current issue of the Journal of Cell Biology about the "tafazzin" protein, which plays a key role in Barth syndrome. This rare condition afflicts boys and damages the heart, immune system and mitochondria. If not diagnosed, boys with the disease have only a 30 percent chance of survival to age 4; the cause of death is often cardiac failure. Mutations in the tafazzin gene lead to Barth syndrome, said Koehler, who noted that tafazzin is named after an Italian cartoon character.

Barth syndrome appears to be a disease of the mitochondria, the tiny power generators in cells that burn food and produce most of the cells' energy. Each human cell contains several hundred mitochondria. Mitochondria control cell growth, tell cells when to live and die, and are, Koehler said, the "forgotten part of the cell."

Koehler and Claypool are the first scientists to show where the tafazzin protein normally is located and where it has moved in some patients with Barth syndrome who have a plethora of different disease-causing mutations. Human mitochondria have what can be considered four "rooms": a matrix, an inner membrane, an intermembrane space and an outer membrane. Claypool discovered that the tafazzin protein is in the mitochondria, normally in the inner and outer membranes' lining, facing the intermembrane space in a unique way.

"We have shown that tafazzin associates with both the outer membrane and the inner membrane, always facing the intermembrane space," Claypool said. "Tafazzin protrudes into the intermembrane space from both the outer and inner membranes. To define a protein's function, it is critical to know its location in the cell."

In Barth syndrome patients who carry the mutations Koehler and Claypool have characterized, the protein has moved into the mitochondria's matrix, and thus is not in the right "room" to function properly. The chemists modeled each of the mutations in baker's yeast tafazzin; baker's yeast, which is a single-cell organism whose mitochondria are very similar to those of human cells, allows for sophisticated genetic experiments.

"What we are doing is impossible to study in human mitochondria," said Koehler, a member of UCLA's Jonsson Cancer Center, Molecular Biology Institute and the Brain Research Institute. "We can make these yeast mitochondria easily and knock down particular genes to provide insights into humans."

"Three of the mutations were mislocalized to the mitochondrial matrix; the fourth mutation we characterized localized normally but was assembled inappropriately," Claypool said. "The mislocalization or misassembly of these mutants disturbed the dance of biology and inactivated tafazzin's function."

Three years ago, when Claypool joined Koehler's laboratory after earning his Ph.D. in immunology from Harvard, almost nothing was known about the tafazzin protein.

Koehler and Claypool believe the tafazzin protein may be associated with cardiolipin, the signature lipid of mitochondria, which has been implicated in other diseases, including those of the heart. Lipids are the major constituent of membranes, which form the barriers in cells.

Is damage from heart attacks caused by problems with cardiolipin? The answer is not yet known, Koehler said.

"In cardiac disease, mitochondria often malfunction," Koehler said. "Cardiolipin is an important lipid in this process; if it becomes damaged, the mitochondria become leaky and do not function as well. Tafazzin may be important in repairing lipids, including cardiolipin, but we have not shown that yet. A better understanding of the biology of cardiolipin could present strategies for combating cardiac diseases and cancer."

Cancers are also associated with defects in mitochondria, Koehler said. Within the cell, signaling must occur between the mitochondria and the nucleus. When the signaling from the mitochondria malfunctions, the defect can cause cancer, she said. Cardiolipin may play a role in critical signaling pathways.

"The fact that you can study a disease that affects the human heart in a single-cell organism that lacks a heart and come up with relevant information is amazing," Claypool said.

Tafazzin's association with both the outer membrane and the inner membrane is consistent with its ability to modify a membrane component such as cardiolipin, Claypool said. Tafazzin might play a "surveillance" role in the mitochondria, the chemists said.

The research was funded by the American Heart Association and the National Institutes of Health. A co-author of the study, published in the July 31 issue of the Journal of Cell Biology (http://www.jcb.org), is J. Michael McCaffery of Johns Hopkins University's Integrated Imaging Center.

Koehler's laboratory studies mitochondrial diseases -- and how defects in mitochondrial function lead to disease -- by using model systems in which they can study the biochemistry in a way they cannot with humans. (Her research team also uses zebrafish as a model system.)

Mitochondria may play a more important role in human health than scientists and doctors have realized, Koehler believes.

Parkinson's appears to be a mitochondrial disease, she said. Types of blindness and deafness are caused by defects in mitochondria. Koehler's laboratory also is studying programmed cell death, or how a cell knows when to die. The pathways start in the mitochondria, she said.

As we age, our mitochondria become less efficient, which could lead to heart problems, as well as loss of hearing and vision, said Koehler, whose future research may help answer whether such health problems are caused by an inability to assemble mitochondria properly.

Is there a link between the deterioration of mitochondrial functioning that occurs as we age and the common problems many of the elderly have with hearing, vision, memory loss and decreased cardiac functioning?

"I think we should consider the possibility," Koehler said. "Any health concern that's an energy problem could be related to mitochondrial assembly. I hope my research will answer fundamental questions about these processes."

Mitochondria, which look very much like bacteria, are descendants of free-living bacteria, which the ancestors of today's cells captured about 1.5 billion years ago as energy-producing "slaves," Koehler said. Over time, the captives became integral parts of their hosts, transferring most of their DNA to the host nucleus. The tiny fraction of the DNA they retained can specify only a handful of the proteins. While a mitochondrion is made up of hundreds of different proteins, the vast majority of these are made outside the mitochondrion and then imported inside. Each imported mitochondrial protein has a specific "address" that is read by machinery for delivering proteins to their correct destination within the mitochondria. This machinery consists of many dozens of proteins and consumes a substantial amount of energy. How this machine works is not well-understood; discovering its mechanics is a major research goal of the research team.

Koehler conducts research in biochemistry, genetics and cell biology to study how mitochondria are assembled and function, how proteins enter the mitochondria and reach the right location inside, and how mitochondria communicate with the rest of the cell.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Los Angeles. "Chemists' Study Of Protein May Provide Insights Into Heart Disease And Cancer." ScienceDaily. ScienceDaily, 11 August 2006. <www.sciencedaily.com/releases/2006/08/060810212733.htm>.
University of California - Los Angeles. (2006, August 11). Chemists' Study Of Protein May Provide Insights Into Heart Disease And Cancer. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2006/08/060810212733.htm
University of California - Los Angeles. "Chemists' Study Of Protein May Provide Insights Into Heart Disease And Cancer." ScienceDaily. www.sciencedaily.com/releases/2006/08/060810212733.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins